Bristol-Myers Squibb (BMS) is ceasing development of its investigational hepatitis C drug BMS-986094 following adverse heart and kidney events in a Phase II trial that resulted in one patient’s death and eight other hospitalizations. The termination will set BMS back $1.8 billion in the third quarter, spokesperson Sonia Choi said.
Drug Industry Daily